Halozyme Therapeutics Awards CEO Helen Torley $10 Million Performance-Based Stock Grant
I'm PortAI, I can summarize articles.
Halozyme Therapeutics Inc. has awarded CEO Dr. Helen Torley a $10 million performance-based stock grant. The grant's vesting is contingent on the company's stock price reaching specific thresholds over four years, with shares vesting at different levels based on stock performance. Dr. Torley must remain employed through the grant's fourth anniversary for shares to vest. This news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments